Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

De Lóa-studie: een korte digitale interventie voor vrouwen met opdringerige herinneringen in het SAGA-cohort

10 november 2026 bijgewerkt door: Arna Hauksdottir, University of Iceland

De Lóa-studie: een gerandomiseerde controleproef van een korte digitale interventie ter ondersteuning van vrouwen die tijdens hun leven opdringerige herinneringen aan traumatische gebeurtenissen ervaren uit het SAGA-cohort

Intrusive memories are sensory memories of a traumatic event(s) that spring to mind involuntarily, and can evoke strong emotions and disrupt functioning in daily life. Previous research has indicated that a brief cognitive intervention can prevent the development of intrusive memories as well as reduce the number of intrusive memories of long-standing trauma. Initial pilot work (using case studies and a pilot study, ClinicalTrials.gov identifier: NCT05089058) with women in Iceland indicates that the intervention is acceptable and feasible.

This randomised controlled trial will compare 3 arms to investigate if access to a cognitive task - either a brief self-guided imagery-competing task or a brief self-guided psychoeducation and signposting task - versus treatment as usual, can reduce the number of intrusive memories in week 5 (i.e., between-groups comparison), controlling for the number of intrusive memories in the baseline week.

The effect on the number of intrusive memories in week 5 (primary outcome), and other symptoms of post-traumatic stress, sleep and cognitive functioning will be tested.

This study is funded by the Icelandic Research Fund (11709-0270) and (200095-5601) and The Oak Foundation (OCAY-18-442).

Studie Overzicht

Gedetailleerde beschrijving

Participants will be recruited from the Stress and Gene Analysis (SAGA) Cohort, a population-based, longitudinal study of Icelandic women (www.afallasaga.is, see selected publications in the reference box below).

A statistical analysis plan will be prepared prior to the first interim analysis using both frequentist and Bayesian analyses for statistical inference.

Regular monitoring will be performed by Vistor to verify that the study is conducted, and data are generated, documented and reported in compliance with the protocol, good clinical practice (GCP) and the applicable regulatory guidelines.

Studietype

Ingrijpend

Inschrijving (Werkelijk)

320

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

      • Reykjavik, IJsland, 102
        • University of Iceland, Sæmundargata 12

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar tot 73 jaar (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Ja

Geslachten die in aanmerking komen voor studie

Vrouw

Beschrijving

Inclusion Criteria:

  • Part of the SAGA cohort
  • Aged 18 or above.
  • Able to read, write and speak in Icelandic.
  • Have internet access.
  • Willing to be contacted remotely and having access to a smartphone or computer
  • Experience 3 or more intrusive memories in the past week
  • Willing to monitor intrusive memories in everyday life
  • Willing and able to provide informed consent and complete study procedures
  • Willing and able to be contacted by the research team during the study period.
  • Have not taken part in a previous study of this intervention from this research team (e.g., the Loa case series, feasibility trial or pilot RCT).

Exclusion Criteria:

  • Have fewer than three intrusive memories during the baseline week.
  • Suicide risk in the initial assessment (response of 'nearly every day' to item 9 on PHQ-9).
  • Those undergoing other treatments for post-traumatic stress disorder (PTSD) or its symptoms will not be excluded, so the study will be as inclusive as possible.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Enkel

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Brief imagery-competing task

Access to a brief imagery-competing task for 24 weeks (with optional researcher support during the study)

Two digital self-guided sessions of a brief digital imagery-competing task. A memory cue followed by playing a computer game with mental rotation instructions.

Experimenteel: Brief psychoeducation and signposting task

Access to psychoeducation and signposting regarding resources for psychological trauma in Iceland for 24 weeks (with optional researcher support during the study)

Two digital self-guided sessions and access to psychoeducation and signposting regarding resources for psychological trauma in Iceland.

Ander: Treatment as usual (TAU)

Routine care that participants would otherwise receive if having intrusive memories of traumatic events.

Routine care that participants would otherwise receive if having intrusive memories of traumatic events

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Number of intrusive memories of traumatic event(s)
Tijdsspanne: Week 5 (all arms) controlling for run-in/baseline week

The number of intrusive memories of traumatic events recorded by participants in a brief daily online intrusive memory diary for 7 days.

Week 5 (all arms) controlling for run-in/baseline week

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Number of intrusive memories of the traumatic event(s)
Tijdsspanne: Week 12 and week 24 follow-ups (all arms) controlling for run-in/baseline week

The number of intrusive memories of traumatic events recorded by participants in a brief daily online intrusive memory diary for 7 days.

Week 12 and week 24 follow-ups (all arms) controlling for run-in/baseline week
The Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5)
Tijdsspanne: Baseline, week 5, week 12 and week 24 follow-ups

A 20-item questionnaire assessing the severity of PTSD symptoms corresponding to the DSM-5 criteria for PTSD. Items are rated on a 5-point Likert scale ranging from 0 ("not at all") to 4 ("extremely"). Scores are summed to give a total severity score (ranging 0 to 80).

Baseline, week 5, week 12 and week 24 follow-ups
The Pittsburgh Sleep Quality Index Addendum for PTSD (PSQI-A)
Tijdsspanne: Baseline, week 5, week 12 and week 24 follow-ups

A 7-item questionnaire assessing the frequency of disruptive nocturnal behaviours (e.g., acting out dreams, episodes of terror or screaming). Respondents report symptoms over the past month on a 4-point Likert scale, ranging from 0 ("never in the past month") to 3 ("three or more times each week"). Total score ranges from 0 to 21 with higher scores indicating worse symptoms.

Baseline, week 5, week 12 and week 24 follow-ups
Cognitive Functions Scale
Tijdsspanne: Baseline, week 5, week 12 and week 24 follow-ups

An 11 item questionnaire about cognitive functions in particular memory and concentration. Items are rated on a 5-point scale, from 1 ("every day") to 5 ("never"). Total scores range from 11 to 55; higher scores indicate less concentration and memory difficulties.

Baseline, week 5, week 12 and week 24 follow-ups

Andere uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
The Patient Health Questionnaire-9 (PHQ-9)
Tijdsspanne: Baseline, week 5, week 12 and week 24 follow-ups

A 9-item questionnaire assessing depression symptoms and their severity. Items are scored from 0 ( "not at all") to 3 ( "nearly every day"). The total score is the sum of all items and ranges from 0 to 27.

Baseline, week 5, week 12 and week 24 follow-ups
The Generalized Anxiety Disorder-7 scale (GAD-7)
Tijdsspanne: Baseline, week 5, week 12 and week 24 follow-ups

A 7-item questionnaire assessing severity of anxiety symptoms. Items are rated for how often they have bothered the respondent over the last two weeks, from 0 ("not at all") to 3 ("nearly every day"). The total score is the sum of all items and ranges from 0 to 21.

Baseline, week 5, week 12 and week 24 follow-ups
The Sheehan Disability Scale (SDS)
Tijdsspanne: Baseline, week 5, week 12 and week 24 follow-ups

A questionnaire assessing functional impairment across three domains: (1) Work/school, (2) social, and (3) family life. Domains are measured on an 11-point Likert scale, ranging from 0 ("not at all") to 10 ("extremely"). The scale is adapted to assess functional impairment associated with intrusive memories. The total score is the sum of all items and ranges from 0 to 30.

Baseline, week 5, week 12 and week 24 follow-ups
Quality of Life Scale (QOLS)
Tijdsspanne: Baseline, week 5, week 12 and week 24 follow-ups

16-item measure to assess quality of life on a 7-point Likert scale, ranging from 7 ("delighted") to 1 ("terrible"). The domains that are assessed are the following: (1) Social and community activities, (2) material and physical wellbeing, (3) relationships with other people, (4) personal development and fulfilment, and (5) recreation. The total score is the sum of all items and ranges from 16 to 112.

Baseline, week 5, week 12 and week 24 follow-ups
The World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0)
Tijdsspanne: Baseline, week 5, week 12 and week 24 follow-ups

A 12-item questionnaire assessing difficulties due to health conditions, including mental or emotional problems (with reference to intrusive memories). Respondents rate how much difficulty they have had in each area in the past 30 days, from 0 ("none") to 4 ("extreme or cannot do"). The overall score is calculated as a percentage of the maximum possible score (i.e., 48 points). Lower scores indicate better functioning.

Baseline, week 5, week 12 and week 24 follow-ups
General Impact of intrusive memories
Tijdsspanne: Baseline, week 5, week 12 and week 24 follow-ups

2-items measuring the general impact of intrusive memories in terms of level of distress and vividness associated with the intrusions on a 11-point scale (ranging from 0 to 10), rated at the end of each diary week. High scores indicate higher levels of distress/vividness.

Baseline, week 5, week 12 and week 24 follow-ups
Acceptability and feasibility
Tijdsspanne: Week 5

Four questions to assess acceptability and feasibility of the both interventions. Rated on a 11-point scale (0 to 10) to measure the extent to which the individual would recommend the intervention and whether they consider it to be an acceptable way to reduce the frequency of intrusive memories. In addition, in this study, we include 1 item on the type of digital device used and 2 open-ended questions about the experience of using the digital platform.

Week 5
Adverse events (AEs)
Tijdsspanne: Week 5, week 12 and week 24 follow-ups

A free-text response field measuring the occurrence of any health problems since the last contact.

Week 5, week 12 and week 24 follow-ups
Credibility/Expectancy Questionnaire
Tijdsspanne: Right after randomization

6-item questionnaire that rates to what degree the participant finds the intervention credible on a 11-point scale from 0 to 10. High scores indicate greater credibility.

Right after randomization
Feedback Questionnaire
Tijdsspanne: Week 5

A 7-item questionnaire will assess participants' experience of using the intervention. The first five items assess how easy, helpful, distressing, burdensome and interesting participants found the intervention. This was assessed on a 11-point scale ranging from 0 ("not at all") to 10 ("very"). The last 2 free-text items ask how the brief cognitive task could be improved, and for any other comments.

Week 5

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Medewerkers

Onderzoekers

  • Hoofdonderzoeker: Arna Hauksdóttir, PhD, University of Iceland
  • Hoofdonderzoeker: Emily Holmes, PhD, Uppsala University

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

30 oktober 2023

Primaire voltooiing (Werkelijk)

15 april 2026

Studie voltooiing (Werkelijk)

14 september 2026

Studieregistratiedata

Eerst ingediend

27 april 2023

Eerst ingediend dat voldeed aan de QC-criteria

27 april 2023

Eerst geplaatst (Werkelijk)

8 mei 2023

Updates van studierecords

Laatste update geplaatst (Werkelijk)

16 november 2026

Laatste update ingediend die voldeed aan QC-criteria

10 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Aanvullende relevante MeSH-voorwaarden

Andere studie-ID-nummers

  • 22-186

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

JA

Beschrijving IPD-plan

Anonymised research data will be made available on Open Science Framework (OSF) indefinitely

IPD-tijdsbestek voor delen

The aim is to share the Study Protocol and Statistical Analysis Plan upon the last participant completing the last visit. Supporting information mentioned above will be shared indefinitely and with no end date on the Open Science Framework (OSF) platform. The results of the study will be shared through open-access publications.

IPD-toegangscriteria voor delen

Anonymised research data will be made available on Open Science Framework (OSF) indefinitely.

OSF is an open-source web application that is freely accessible to the public and scientific community

IPD delen Ondersteunend informatietype

  • LEERPROTOCOOL
  • SAP

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren